A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer
European Journal of Cancer · 2026-11 · 248 · 117477
DOI: 10.1016/j.ejca.2026.117477 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von R. El Botty und 16 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Botty, R. E., Montaudon, E., Marsolier, J., Jouault, G., Sauge, J., Darrien, H., Courtois, L., Grynszpan, L., Guerin, C., Guillonneau, F., Patsouris, A., Poullet, P., Bieche, I., Coussy, F., Cabel, L., Vallot, C., & Marangoni, E. (2026). A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer. European Journal of Cancer, 248, 117477. https://doi.org/10.1016/j.ejca.2026.117477
Vancouver
Botty RE, Montaudon E, Marsolier J, Jouault G, Sauge J, Darrien H, et al. A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer. European Journal of Cancer. 2026;248:117477. doi:10.1016/j.ejca.2026.117477
BibTeX
@article{Botty2026,
author = {Botty, R. El and Montaudon, E. and Marsolier, J. and Jouault, G. and Sauge, J. and Darrien, H. and Courtois, L. and Grynszpan, L. and Guerin, C. and Guillonneau, F. and Patsouris, A. and Poullet, P. and Bieche, I. and Coussy, F. and Cabel, L. and Vallot, C. and Marangoni, E.},
title = {A proliferative-luminal phenotype predicts trastuzumab deruxtecan sensitivity independent of HER2 expression in ER-positive breast cancer},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117477},
doi = {10.1016/j.ejca.2026.117477}
}
EUVIMED